Balaxi Pharmaceuticals Ltd (BALAXI) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 999933, "name": "Balaxi Pharma", "stock_name": "Balaxi Pharma", "full_name": "Balaxi Pharmaceuticals Ltd", "name_url": "stocks-analysis/balaxi-pharma", "exchange": 1, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "16.48", "chg": -1.26, "chgp": "-7.1%", "dir": -1, "prev_price": "17.74", "mcapval": "98.00 Cr", "mcap": "Micro Cap", "scripcode": "", "symbol": "BALAXI", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 5, "indexname": "India SENSEX", "isin": "INE618N01022", "curr_date": "Mar 27", "curr_time": "", "bse_nse_vol": 178536, "exc_status": "Active", "traded_date": "Mar 27, 2026", "traded_date_str": "2026 03 27", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/balaxi-pharma-999933-1&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Balaxi Pharmaceuticals Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharmaceuticals-ltd-is-rated-strong-sell-3918818", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BalaxiPharmaceu_mojoScore_3918818.png", "date": "2026-03-27 10:10:41", "description": "Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 27 March 2026, providing investors with the latest perspective on the company’s position." }, { "title": "Balaxi Pharmaceuticals Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharmaceuticals-ltd-is-rated-strong-sell-3892013", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BalaxiPharmaceu_mojoScore_3892013.png", "date": "2026-03-15 10:10:32", "description": "Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 15 March 2026, providing investors with the latest insights into the stock’s performance and outlook." }, { "title": "Balaxi Pharmaceuticals Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharmaceuticals-ltd-is-rated-strong-sell-3866183", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BalaxiPharmaceu_mojoScore_3866183.png", "date": "2026-03-03 10:10:34", "description": "Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed below represent the stock's current position as of 03 March 2026, providing investors with the latest insights into its performance and outlook." }, { "title": "Balaxi Pharmaceuticals Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharmaceuticals-ltd-is-rated-strong-sell-3848057", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BalaxiPharmaceu_mojoScore_3848057.png", "date": "2026-02-20 10:10:49", "description": "Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025, reflecting a reassessment of the company’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 20 February 2026, providing investors with the latest perspective on the stock’s performance and prospects." }, { "title": "Balaxi Pharmaceuticals Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharmaceuticals-ltd-is-rated-strong-sell-3828297", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BalaxiPharmaceu_mojoScore_3828297.png", "date": "2026-02-09 10:11:11", "description": "Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 09 February 2026, providing investors with an up-to-date view of its performance and outlook." }, { "title": "Balaxi Pharmaceuticals Gains 0.91%: 2 Key Factors Driving the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/balaxi-pharmaceuticals-gains-091-2-key-factors-driving-the-week-3812846", "imagepath": "", "date": "2026-01-31 14:01:02", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>Jan 27:</strong> Stock opens week at Rs.24.31, up 0.62%</p>\n <p><strong>Jan 28:</strong> Q3 FY26 results reveal deepening profitability crisis; stock surges 3.41%</p>\n <p><strong>Jan 29:</strong> Flat quarterly performance reported amid long-term challenges; stock retreats 2.94%</p>\n <p><strong>Jan 30:</strong> Week closes at Rs.24.38, marginal decline of 0.08% on the day</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.24.16</div></div>\n <div class=\"stat-item\"><div class=\"stat-la..." }, { "title": "Balaxi Pharmaceuticals Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharmaceuticals-ltd-is-rated-strong-sell-3809058", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/BalaxiPharmaceu_mojoScore_3809058.png", "date": "2026-01-29 10:11:07", "description": "Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 29 January 2026, providing investors with the latest data to inform their decisions." }, { "title": "Balaxi Pharmaceuticals Reports Flat Quarterly Performance Amid Long-Term Challenges", "link": "https://www.marketsmojo.com/news/stocks-in-action/balaxi-pharmaceuticals-reports-flat-quarterly-performance-amid-long-term-challenges-3808617", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/BalaxiPharmaceu_fintrenddot_3808617.png", "date": "2026-01-29 08:00:23", "description": "Balaxi Pharmaceuticals Ltd has reported a flat financial performance for the quarter ended December 2025, marking a notable shift from its previous negative trend. Despite the absence of key negative triggers, the company continues to face significant headwinds, reflected in its long-term stock underperformance relative to the broader market." }, { "title": "Are Balaxi Pharmaceuticals Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-balaxi-pharmaceuticals-ltd-latest-results-good-or-bad-3808239", "imagepath": "", "date": "2026-01-28 19:17:21", "description": "Balaxi Pharmaceuticals Ltd's latest financial results for Q3 FY26 present a complex picture of operational challenges and profitability issues. The company reported net sales of ₹72.54 crores, reflecting a slight decline of 1.02% year-on-year from ₹73.29 crores. This indicates a degree of revenue stability in a competitive environment; however, the net profit plummeted by 94.22% to just ₹0.31 crores, highlighting severe profitability erosion.\n\nThe company's profitability metrics have also shown significant compression. The profit after tax (PAT) margin fell to 0.43%, down from 7.31% in the same quarter last year, while the operating margin decreased to 4.26% from 5.44%. These figures suggest that Balaxi Pharmaceuticals is facing substantial operational inefficiencies and cost pressures, despite a sequential recovery in revenue and net profit compared to the previous quarter.\n\nNotably, the extraordinary tax ..." } ], "total": 98, "sid": "999933", "stock_news_url": "https://www.marketsmojo.com/news/balaxi-pharmaceuticals-999933" }, "announcements": [ { "details": "Balaxi Ventures Limited has informed the Exchange regarding Resignation of Mr Nidhin Jose as Chief Financial Officer of the company w.e.f. November 30, 2019.", "source": "NSE", "caption": "Balaxi Ventures Limited - Resignation", "datetime": "21-Nov-2019" }, { "details": "Balaxi Ventures Limited has informed the Exchange regarding Statement of deviation(s) or variation(s) under Reg. 32 of SEBI (LODR) Regulations 2015", "source": "NSE", "caption": "Balaxi Ventures Limited - Statement of deviation(s) or variation(s) under Reg. 32", "datetime": "30-Oct-2019" }, { "details": "Balaxi Ventures Limited has informed the Exchange regarding Board meeting held on October 29, 2019.", "source": "NSE", "caption": "Balaxi Ventures Limited - Outcome of Board Meeting", "datetime": "29-Oct-2019" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Balaxi Pharmaceuticals Ltd has declared <strong>5%</strong> dividend, ex-date: 01 Jul 22", "dt": "2022-07-01", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Balaxi Pharmaceuticals Ltd has announced <strong>2:10</strong> stock split, ex-date: 30 May 24", "dt": "2024-05-30", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

Jan 27: Stock opens week at Rs.24.31, up 0.62%

Jan 28: Q3 FY26 results reveal deepening profitability crisis; stock surges 3.41%

Jan 29: Flat quarterly performance reported amid long-term challenges; stock retreats 2.94%

Jan 30: Week closes at Rs.24.38, marginal decline of 0.08% on the day

Week Open

Rs.24.16

Read full news article

Balaxi Pharmaceuticals Ltd is Rated Strong Sell

2026-01-29 10:11:07

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 29 January 2026, providing investors with the latest data to inform their decisions.

Read full news article

Balaxi Pharmaceuticals Reports Flat Quarterly Performance Amid Long-Term Challenges

2026-01-29 08:00:23

Balaxi Pharmaceuticals Ltd has reported a flat financial performance for the quarter ended December 2025, marking a notable shift from its previous negative trend. Despite the absence of key negative triggers, the company continues to face significant headwinds, reflected in its long-term stock underperformance relative to the broader market.

Read full news article

Are Balaxi Pharmaceuticals Ltd latest results good or bad?

2026-01-28 19:17:21

Balaxi Pharmaceuticals Ltd's latest financial results for Q3 FY26 present a complex picture of operational challenges and profitability issues. The company reported net sales of ₹72.54 crores, reflecting a slight decline of 1.02% year-on-year from ₹73.29 crores. This indicates a degree of revenue stability in a competitive environment; however, the net profit plummeted by 94.22% to just ₹0.31 crores, highlighting severe profitability erosion. The company's profitability metrics have also shown significant compression. The profit after tax (PAT) margin fell to 0.43%, down from 7.31% in the same quarter last year, while the operating margin decreased to 4.26% from 5.44%. These figures suggest that Balaxi Pharmaceuticals is facing substantial operational inefficiencies and cost pressures, despite a sequential recovery in revenue and net profit compared to the previous quarter. Notably, the extraordinary tax ...

Read full news article